EPH131 Estimation of the Population of Patients Eligible for Pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) Discontinuation in the United States
Abstract
Authors
K.H. Zhang K. Winfree K.L. Taipale C.E. Muehlenbein E.H. Panjic C. Graham